Wealth Science Advisors LLC Acquires Shares of 2,341 Eli Lilly and Company $LLY

Key Points

• Wealth Science Advisors LLC initiated a new stake in Eli Lilly of 2,341 shares valued at about $2.516 million, representing roughly 1.5% of its portfolio and making LLY its 14th largest holding.
• Eli Lilly beat Q1 estimates with EPS of $7.54 vs. $7.48 and revenue of $19.29 billion (up 42.6% year‑over‑year), and set FY2026 guidance of 33.5–35.0 EPS.
• Lilly is expanding its oncology pipeline (agreed to buy Ajax Therapeutics for up to $2.3 billion) while facing GLP‑1 competitive pressure from Boehringer and Novo Nordisk’s Wegovy tablet, producing mixed analyst reactions and an average price target near $1,216.52.

Wealth Science Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,341 shares of the company's stock, valued at approximately $2,516,000. Eli Lilly and Company comprises approximately 1.5% of Wealth Science Advisors LLC's portfolio, making the stock its 14th largest holding.

Other institutional investors also recently modified their holdings of the company. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth $25,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $33,000. Dorato Capital Management bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $36,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after buying an additional 16 shares in the last quarter. Finally, 10Elms LLP increased its position in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.7%

Shares of NYSE:LLY opened at $868.59 on Tuesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a market capitalization of $820.66 billion, a P/E ratio of 37.85, a price-to-earnings-growth ratio of 1.05 and a beta of 0.51. The company has a 50-day simple moving average of $955.40 and a 200 day simple moving average of $985.96. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm's quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to buy Ajax Therapeutics for up to $2.3B, adding a first‑in‑class Type II JAK2 program (AJ1‑11095) for myelofibrosis and polycythemia vera — strengthens Lilly’s hematology/oncology pipeline and complements recent oncology deals. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: Lilly continues to bolster oncology via the Kelonia deal (reported earlier), a strategic shift that diversifies revenues beyond GLP‑1s and supports longer‑term growth expectations. Eli Lilly and Company (LLY): Among the Best Stocks to Buy While the Market Is Down
• Positive Sentiment: Some sell‑side analysts remain bullish after recent M&A: Barclays reiterated Overweight with a $1,350 target, underscoring confidence in Lilly’s multi‑franchise strategy. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Wall Street is focused on Q1 results and guidance — Zacks and other previews highlight GLP‑1 sales, pricing pressure, and Foundayo uptake as key metrics to watch; earnings will likely drive near‑term moves. Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
• Neutral Sentiment: Broader health‑care weakness pressured the group late Monday, which can amplify LLY moves independent of company‑specific news. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: Competitor Boehringer Ingelheim reported a late‑stage obesity drug producing ~16.6% average weight loss — fresh competitive data that could weigh on Lilly’s GLP‑1 market share and pricing power. Boehringer‑Zealand drug leads to 16.6% weight loss in late‑stage trial
• Negative Sentiment: Data and prescription trends show Lilly’s oral Foundayo trailing Novo Nordisk’s Wegovy tablet in early weeks — raises near‑term adoption concerns for Lilly’s obesity franchise. GLP‑1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: Leerink lowered its price target on LLY from $1,296 to $1,058 (still Outperform) — a sign some analysts are trimming expectations given launch dynamics and pricing risk. Leerink Partners adjusts PT on Eli Lilly and Co to $1,058 from $1,296 — maintains Outperform

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Barclays initiated coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 price target on the stock. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. BMO Capital Markets reissued an "outperform" rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, HSBC downgraded Eli Lilly and Company from a "hold" rating to a "reduce" rating and dropped their price target for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,216.52.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.